Search
Search
About
Log in
Join
Experiences with
Nivolumab
Posts
Communities
122 public posts
Filter results
Exclusive Fasttrak - Apply to clinical trial testing a new immunotherapy for prostate cancer!
What if you could get access to free immunotherapy treatment using
Nivolumab
, also known as OPDIVO? Opdivo is used for other cancer types, but has not yet been approved for prostate cancer. Opdivo is a medicine that may treat certain cancers by working with your immune system.
What if you could get access to free immunotherapy treatment using
Nivolumab
, also known as OPDIVO? Opdivo is used for other cancer types, but has not yet been approved for prostate cancer. Opdivo is a medicine that may treat certain cancers by working with your immune system.
Darryl
Partner
in
Advanced Prostate Cancer
4 years ago
Claim your spot in Immunotherapy Trial testing Opvido for prostate cancer. Hurry, please
Malecare, along with our partners, is prescreening our community for a study of Opvido (
Nivolumab
) or Placebo in Combination With Docetaxel in men With Advanced Castration-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Malecare, along with our partners, is prescreening our community for a study of Opvido (
Nivolumab
) or Placebo in Combination With Docetaxel in men With Advanced Castration-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Darryl
Partner
in
Advanced Prostate Cancer
4 years ago
Enter trial of Opvido (Nivolumab) or Placebo in Combination With Docetaxel in men With Advanced Castration-resistant Prostate Cancer- Hurry
Malecare, along with our partners, is prescreening our community for a study of Opvido (
Nivolumab
) or Placebo in Combination With Docetaxel in men With Advanced Castration-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Malecare, along with our partners, is prescreening our community for a study of Opvido (
Nivolumab
) or Placebo in Combination With Docetaxel in men With Advanced Castration-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application.
Darryl
Partner
in
Advanced Prostate Cancer
4 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Has anyone received the Covid-19 Vaccine while taking Immunotherapy?
Fellow cancer patients, I have been very concerned about how my immunotherapy (Opdivo/
nivolumab
) might affect my body’s response to the Covid-19 vaccine. During my past year on this treatment, my immune system has “overresponded” on several occasions as can be a side-effect of the treatment.
Fellow cancer patients, I have been very concerned about how my immunotherapy (Opdivo/
nivolumab
) might affect my body’s response to the Covid-19 vaccine. During my past year on this treatment, my immune system has “overresponded” on several occasions as can be a side-effect of the treatment.
Jenniferroseolson
in
Lung Cancer Support
4 years ago
Chemotherapy Dacarbozine vs Nivo: 5 year outcomes
This study compares using a chemotherapy drug dacarbazine vs
nivolumab
(Optivo) with Wild Type Stage 3-4 melanoma adding to body of evidence that PD-1's have superior outcomes for overall survival to 5 years in melanoma patients, regardless of BRAF type. But we still have a long way to go.
This study compares using a chemotherapy drug dacarbazine vs
nivolumab
(Optivo) with Wild Type Stage 3-4 melanoma adding to body of evidence that PD-1's have superior outcomes for overall survival to 5 years in melanoma patients, regardless of BRAF type. But we still have a long way to go.
missyrand
Ambassador
in
Melanoma Caregivers
4 years ago
Scan update
Other trials have tried
nivolumab
and ipilimumab - but not Keytruda with ipilimumab. I will get details of these other treatment options and let you guys know to see if it’s something that could be useful to the community. But right now me and Ryan are over the moon with these results.
Other trials have tried
nivolumab
and ipilimumab - but not Keytruda with ipilimumab. I will get details of these other treatment options and let you guys know to see if it’s something that could be useful to the community. But right now me and Ryan are over the moon with these results.
kellyOd
in
Melanoma Caregivers
4 years ago
Dual Immunotherapy Prolongs Survival While Avoiding Chemotherapy in Malignant Pleural Mesothelioma
Data from a prespecified interim analysis, based on a minimum follow-up of 22 months, showed that combined treatment with
nivolumab
and ipilimumab yielded a 4-month improvement in median overall survival (OS) as compared with platinum doublet chemotherapy (18.1 vs 14.1 months; hazard ratio [HR] 0.74,
Data from a prespecified interim analysis, based on a minimum follow-up of 22 months, showed that combined treatment with
nivolumab
and ipilimumab yielded a 4-month improvement in median overall survival (OS) as compared with platinum doublet chemotherapy (18.1 vs 14.1 months; hazard ratio [HR] 0.74,
2greys
in
Lung Conditions Community Forum
4 years ago
Treatment after chemo - PARP inhibitor or immunotherapy trial?
But, there is an immunotherapy trial,
nivolumab
and ipilimumab, at MD Anderson that my MO suggests I try. She also indicated we might try the PARP inhibitor with the immunotherapy. At some point, I assume I will try Lu-177 and Ac-225.
But, there is an immunotherapy trial,
nivolumab
and ipilimumab, at MD Anderson that my MO suggests I try. She also indicated we might try the PARP inhibitor with the immunotherapy. At some point, I assume I will try Lu-177 and Ac-225.
WhiteStrat
in
Advanced Prostate Cancer
4 years ago
HCC (hepato cellular carcinoma ) patient survey
Have you been diagnosed with HCC and are currently on oral systemic therapy drug treatment for liver cancer (for example, sorafenib, regorafenib,
nivolumab
, lenvatinib, pembrolizumab, or cabozantinib)? If so, we’d like to ask for your help.
Have you been diagnosed with HCC and are currently on oral systemic therapy drug treatment for liver cancer (for example, sorafenib, regorafenib,
nivolumab
, lenvatinib, pembrolizumab, or cabozantinib)? If so, we’d like to ask for your help.
Hidden
Partner
in
British Liver Trust
4 years ago
FDA Approves nivolumab Plus ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC
Here is the link for full press release: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-
nivolumab
-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc
Here is the link for full press release: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-
nivolumab
-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc
Miranda_GO2
Partner
in
Lung Cancer Support
4 years ago
Starting Chemo & Immunotherapy this week
My husband, Stevana on this site, finally has a date to start chemotherapy (Docetaxel) along with immunotherapy (Opdivo/
Nivolumab
) on August 13th. He was diagnosed on March 26, 2020. Because of extensive bone metastasis and lymph node involvement, he was not a candidate for surgery or radiation.
My husband, Stevana on this site, finally has a date to start chemotherapy (Docetaxel) along with immunotherapy (Opdivo/
Nivolumab
) on August 13th. He was diagnosed on March 26, 2020. Because of extensive bone metastasis and lymph node involvement, he was not a candidate for surgery or radiation.
Avanat
in
Advanced Prostate Cancer
4 years ago
ASCO reporting: IPI with NIVO combo has better outcome than NIVO alone
https://www.oncnet.com/news/
nivolumab
-plus-ipilimumab-extends-tfs-over-
nivolumab
-alone-advanced-melanoma Report out on about 1000 patients comparing IPI/NIVO combo vs NIVO alone for metastatic melanoma. TFS = treatment free survival. Peace, and be safe, Missy
https://www.oncnet.com/news/
nivolumab
-plus-ipilimumab-extends-tfs-over-
nivolumab
-alone-advanced-melanoma Report out on about 1000 patients comparing IPI/NIVO combo vs NIVO alone for metastatic melanoma. TFS = treatment free survival. Peace, and be safe, Missy
missyrand
Ambassador
in
Melanoma Caregivers
4 years ago
Opdivo and Yervoy combination approved for Non-small cell lung cancer
The approval of Opdivo (
nivolumab
) and Yervoy (ipilimumab) marks the first approval of combined immunotherapy treatment for NSCLC. This gives patients whose cancer does not have a targetable change a new avenue for treatment and more options than they have ever had.
The approval of Opdivo (
nivolumab
) and Yervoy (ipilimumab) marks the first approval of combined immunotherapy treatment for NSCLC. This gives patients whose cancer does not have a targetable change a new avenue for treatment and more options than they have ever had.
Miranda_GO2
Partner
in
Lung Cancer Support
4 years ago
Do you have liver cancer?
Do you have liver cancer? Urgent help needed We are looking for one or two patients who have liver cancer and are currently being treated by systemic drug therapy (e.g. regorafenib, nivolu¬mab, lenvatinib, pembrolizumab, and cabozantinib) to help us with the design of a patient survey. A small honorarium
Do you have liver cancer? Urgent help needed We are looking for one or two patients who have liver cancer and are currently being treated by systemic drug therapy (e.g. regorafenib, nivolu¬mab, lenvatinib, pembrolizumab, and cabozantinib) to help us with the design of a patient survey. A small honorarium
Hidden
British Liver Trust
in
British Liver Trust
4 years ago
New treatment
Then i had a drip of
Nivolumab
for 30 mins. This will happen every other week for 6 weeks then once every 30 days after that.
Then i had a drip of
Nivolumab
for 30 mins. This will happen every other week for 6 weeks then once every 30 days after that.
nextphase
in
Advanced Prostate Cancer
4 years ago
ippi and Nivolumab
The immunotherapy combo was to start today but the insurance company denied approval. Any tips or advice of how to get a access to this combo? Trials are out due to a secondary cancer my hubs has.
The immunotherapy combo was to start today but the insurance company denied approval. Any tips or advice of how to get a access to this combo? Trials are out due to a secondary cancer my hubs has.
Blair77
in
Advanced Prostate Cancer
4 years ago
Anyone have any direct experience with the COMBAT trial? BAT with Nivolumab
I have a friend considering it Any insight would help
I have a friend considering it Any insight would help
Longterm101
in
Advanced Prostate Cancer
4 years ago
Possibility of Lymphangitis Carcinomatosis as a consequence of HCC.
They have started steroids and are recommending Lenvatinib (chemotherapy) and / or
Nivolumab
(immunotherapy).
They have started steroids and are recommending Lenvatinib (chemotherapy) and / or
Nivolumab
(immunotherapy).
Jabba2
in
Blue Faery Liver Cancer
4 years ago
Richter’s treatment started
Yesterday I began my Richter’s treatment journey:
Nivolumab
(Opdivo) infusion at Moffitt twice a month for two months with daily 420mg Ibrutinib. The infusion was easy and lasted in total for less than an hour. By the end of day I felt a little queasy, but feel nearly normal today.
Yesterday I began my Richter’s treatment journey:
Nivolumab
(Opdivo) infusion at Moffitt twice a month for two months with daily 420mg Ibrutinib. The infusion was easy and lasted in total for less than an hour. By the end of day I felt a little queasy, but feel nearly normal today.
SarasotaPaul
in
CLL Support
5 years ago
BRAF-Mutated Metastatic Melanoma: Recent Research ContextStill a question about the best frontline therapy
Second, the CR rates with
nivolumab
plus ipilimumab are much higher than with anti-PD1 alone or BRAF/MEK inhibitors (22% vs 19% versus 16%, respectively).
Second, the CR rates with
nivolumab
plus ipilimumab are much higher than with anti-PD1 alone or BRAF/MEK inhibitors (22% vs 19% versus 16%, respectively).
missyrand
Ambassador
in
Melanoma Caregivers
5 years ago
1
2
3
4
...
7
Next page
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
50 results
The Roy Castle Lung Cancer Foundation
19 results
Lung Cancer Support
12 results
View top 10 communities
Sort by
Most Relevant
Newest